健择联合卡铂、长春瑞滨治疗晚期非小细胞肺癌临床观察  

Clinical observation of Gemcitabine combined with Carboplatin,Vinorelbine Bitartrate in treatment of advanced None-small cell lung cancer

作　　者：彭蕻琳[1] 徐轶 陈小可[1] 

机构地区：[1]深圳市第四人民医院,518033

出　　处：《中国现代药物应用》2009年第13期13-15,共3页Chinese Journal of Modern Drug Application

摘　　要：目的观察比较健择联合卡铂、长春瑞滨(GCN方案)与健择联合长春瑞滨(GN方案)治疗晚期非小细胞肺癌(NSCLC)的疗效和毒副反应。方法68例晚期NSCLC患者随机分成GCN方案组38例及GN方案组30例。每例至少治疗两个周期。结果GCN组及GN组有效率分别为52.6%及26.7%(P<0.05),中位疾病进度时间分别为9个月及4个月。中位生存期分别为15个月及9个月。毒副反应以骨髓抑制为主,GCN组略高(P>0.05),胃肠道反应轻微。结论GCN方案治疗NSCLC近期疗效略高于GN方案,毒性反应可耐受。Objective Observation and comparison of treatment effect and toxicity reaction between GCN progranune （Gemcitabine combined with Carboplatin and Vinorelbine Bitatrate ） and GN programme （Gemcitabine combined with Vinorelbine Bitatrate） in treatment of advanced None-small cell lung cancer. Methods 68 patients of None-small cell lung cancer （NSCLC） is divided into GCN section （ 38 cases） and GN section （30 cases） randomly. Each patient will be treated at least for 2 cycles. Result The effective rate of GCN section and GN section is 52. 6% and 26. 7% respectively （P 〈 0.05 ） while ITP is 9 months and 4 months respectively, MST （median survival time） is 15 months and 9 months respectively as well. Main toxicity reaction is slightly more observed as myelosuppression in GCN section （P 〉 0. 05 ）, mild gastrointestinal reaction is also found in both sections. Conclusion Short-term effect to NSCLC by GCN is slightly higher than that of CN, and toxicity reaction is tolerated.

关 键 词：健择 卡铂 长春瑞滨 非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R521[医药卫生—临床医学]